Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocardial viability?

Clinical Cardiology

Volumn 21, Issue 4, 1998, Pages 235-242

  Caner, Biray ^a   Beller, George A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

(99m)Tc tetrofosmin; Coronary artery disease; Left ventricular dysfunction; Myocardial perfusion imaging; Radionuclide imaging; Technetium 99m sestamibi ((99m)Tc); Thallium 201

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; THALLIUM 201;

CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART SCINTISCANNING; ISCHEMIC HEART DISEASE; RADIATION ATTENUATION; REVIEW; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STUNNED HEART MUSCLE;

EID: 0031953166     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960210402     Document Type: Review

References (79)

1. Iskandrian A, Heo J, Stanberry C: When is myocardial viability an important clinical issue? J Nucl Med 1994:35(suppl):4S-7S
2. Schoeder H, Friedrich M, Topp H: Myocardial viability: What do we need? Eur J Med 1993;20:792-803
3. Gimple LW, Belier GA: Myocardial viability: Assessment by cardiac scintigraphy. Cardiol Clin 1994;12:317-332
4. Hendel RC: Single-photon perfusion imaging for the assessment of myocardial viability. J Nucl Med 1994:35(suppl):23S-31S
5. Jain D, Zaret BL: Nuclear imaging techniques for the assessment of myocardial viability. Cardiol Clin 1995:13:43-57
6. McGhie AI, Weyman A: Searching for hibernating myocardium. Time to reevaluate investigative strategies? (editorial) Circulation 1996;94:2685-2688
7. Dilsizian V: Myocardial viability: Contractile reserve or cell membrane integrity? (editorial) J Am Coll Cardiol 1996;28:443-446
8. Saha GB, Maclntyre WJ, Brunken RC, Go RT, Raja S, Wong CO, Chen EQ: Present assessment of viability by nuclear imaging. Semin Nucl Med 1996;26:315-335
9. Hendel RC, Chaudhry FA, Bonow RO: Myocardial viability. Curr Probl Cardiol 1996;21:145-221
10. Bonow RO: The hibernating myocardium: Implications for management of congestive heart failure. Am J Cardiol 1995;75:17A-25A
11. 201Tl scintigraphy and low-dose dobutamine echocardiography for the noninvasive assessment of myocardial viability (editorial). Circulation 1996;94:2681-2684
12. Gioia G, Powers J. Heo J, Iskandrian AS: Prognostic value of restredistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardiol 1995;75:759-762
13. DiCarli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, Czernin J, Rokhsar S, Stevenson LW, Laks H, Hawkins R, Scheiben HR, Phelps ME, Maddahi J: Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-533
14. Schelbeet HR: Metabolic imaging to assess myocardial viability. J Nucl Med 1994;35(suppl):8S-14S
15. Bergmann SR: Use and limitations of metabolic tracers labeled with positron-emitting radionuclides in identification of viable myocardium. J Nucl Med 1994;35(suppl):15S-22S
16. 18F-fluorodeoxyglucose. Circulation 1991;83:26-37
17. Dilsizian V, Freedman NM, Bacharach SL, Perrone-Filardi P, Bonow RO: Regional thallium uptake in irreversible defects. Magnitude of change in thallium activity after reinjection distinguishes viable from nonviable myocardium. Circulation 1992;85:627-634
18. Schafers M, Matheja P, Hasfeld M, Bartenstein P, Lerch H, Breithardt G, Scheid H, Schober O: The clinical impact of thallium-201 reinjection for the detection of myocardial hibernation. Eur J Nucl Med 1996;23:407-413
19. Cuocolo A, Pace L, Ricciardalli B, Chiariello M, Trimarco B, Salvatore M: Identification of viable myocardium in patients with chronic coronary artery disease. Comparison of thallium-201 scintigraphy with reinjection and technetium-99m-methoxyisobutyl isonitrile. J Nucl Med 1992;33:505-511
20. Maurea S, Cuocolo A, Nicolai E, Salvatore M: Improved detection of viable myocardium with thallium-201 reinjection in chronic coronary artery disease: Comparison with technetium-99m-MIBI imaging. J Nucl Med 1994;35:621-624
21. Marzullo P, Sambuceti G, Parodi O: The role of sestamibi scintigraphy in the radioisotopic assessment of myocardial viability. J Nucl Med 1992;33:1925-1930
22. Sawada SG, Allman KC, Muzik O, Beanlands RS, Wolfe ER Jr, Gross M, Fig L, Schwaiger M: Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 1994;23:92-98
23. 18F] fluorodeoxyglucose [erratum, Circulation 1995;91:3026]. Circulation 1994;89:578-587
24. 99mTc-MIBI SPET: A comparative study in patients with coronary artery disease. Eur J Nucl Med 1992;19:334-342
25. Verani MS, Jeroudi MO, Mahmarian JJ, Boyce TM, Borges-Neto S, Patel B, Bolli R: Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxyisobutyl isonitrile. J Am Coll Cardiol 1988;12:1573-1581
26. Freeman I, Grunwald AM, Hoory S, Bodenheimer MM: Effect of coronary occlusion and myocardial viability on myocardial activity of technetium-99m-sestamibi. J Nucl Med 1991;32:292-298
27. Sinusas AJ, Watson DD, Cannon JM Jr, Beller GA: Effect of ischemia and postischemic dysfunction on myocardial uptake of technetium-99m-Iabeled methoxyisobutyl isonitrile and thallium-201. J Am Coll Cardiol 1989;14:1785-1793
28. Beanlands RS, Dawood F, Wen WH, McLaughlin PR, Butany J, D'Amati G, Liu PP: Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability? Circulation 1990;82:1802-1814
29. 99mTc-sestamibi uptake and retention during myocardial ischemia and reperfusion. Circulation 1993;87:2033-2042
30. 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction. Circulation 1989;80:1277-1286
31. Maublant JC, Citron B, Lipiecki J, Mestas D, Bailly P, Veyre A, de Riberolles C, Ponsonnaille J: Rest technetium-99m-sestamibi tomoscintigraphy in hibernating myocardium. Am Heart J 1995;129:306-314
32. 99mTc-sestamibi. Circulation 1994;89:2552-2561
33. Leavitt JI, Better N, Tow DE, Rocco TP: Demonstration of viable, stunned myocardium with technetium-99m-sestamibi. J Nucl Med 1994;35:1805-1807
34. Macs AF, Borgers M, Flameng W, Nuyts JL, van de Werf F, Ausma JJ, Sergeant P, Mortelmans LA: Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up. J Am Coll Cardiol 1997;29:62-68
35. Kauffman GJ, Boyne TS, Watson DD, Smith WH, Beller GA: Comparison of rest thallium-201 imaging and rest technetium-99m sestamibi imaging for assessment of myocardial viability in patients with coronary artery disease and severe left ventricular dysfunction. J Am Coll Cardiol 1996;27:1592-1597
36. Sansoy V, Glover D, Watson DD, Ruiz M, Smith WH, Simanis JP, Beller GA: Comparison of thallium-201 resting redistribution with technetium-99m-sestamibi uptake and functional response to dobutamine for assessment of myocardial viability. Circulation 1995;92:994-1004
37. Braunwald E, Kloner RA: The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982;66:1146-1149
38. Kloner RA, Allen J, Cox TA, Zheng J, Ruiz CE: Stunned left ventricular myocardium after exercise treadmill testing in coronary artery disease. Am J Cardiol 1991;68:329-334
39. Braunwald E, Rutherford JD: Reversible ischemic left ventricular dysfunction: Evidence for the "hibernating myocardium." J Am Coll Cardiol 1986;8:1467-1470
40. Rahimtoola SH: The hibernating myocardium. Am Heart J 1989;117:211-221
41. Heo J, Herman GA, Iskandrian AS, Askenase A, Segal BL: New myocardial perfusion imaging agents: Description and applications. Am Heart J 1988;115:1111-1117
42. Piwnica-Worms D, Kronauge JF, Chiu ML: Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990;82:1826-1838
43. Okada RD, Glover D, Gaffney T, Williams S: Myocardial kinetics of technetium-99m-hexakis2-methoxy2-memylpropyl-isomtrile. Circulation 1988;77:491-498
44. Crane P, Laliberte R, Heminway S, Thoolen M, Orlandi C: Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993;20:20-25
45. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, Boucher CA, Picard M, Holman BL, Fridrich R, Inglese E, Delaloye B, Bischof-Delaloye A, Camin L, McKusick K: Technetium-99m hexakis 2-methoxyisobutyl isonitrile: Human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-311
46. Kiat H, Maddahi J, Roy LT, Van Train K, Friedman J, Resser K, Berman DS: Comparison of technetium 99m methoxy isobutyl isonitrile and thallium 201 for evaluation of coronary artery disease by planar and tomographic methods. Am Heart J 1989;117:1-11
47. 99mTc-2-methoxy isobutyl isonitrile: A direct comparison in normal individuals and patients with coronary artery disease. Circulation 1989;79:1282-1293
48. Wackers FJ, Gibbons RJ, Verani MS, Kayden DS, Pellikka PA, Behrenbeck T, Mahmarian JJ, Zaret BL: Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: Efficacy for noninvasive assessment of thrombolytic therapy. J Am Coll Cardiol 1989;14:861-873
49. Soufer R, Dey HM, Ng CK, Zaret BL: Comparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability. Am J Cardiol 1995;75:1214-1219
50. Dilsizian V, Perrone-Filardi P, Arrighi J, Bacharach SL, Quyyumi AA, Freedman NM, Bonow RO: Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium. Comparison with metabolic activity by positron emission tomography. Circulation 1993;88:941-952
51. Sciagra R, Bisi G, Santoro GM, Agnolucci M, Zoccarato O, Fazzini PF: Influence of the assessment of defect severity and intravenous nitrate administration during tracer injection on the detection of viable hibernating myocardium with data-based quantitative technetium-99m-labeled sestamibi single-photon emission computed tomography. J Nucl Cardiol 1996;3:221-230
52. 201Tl in the presence of a severe coronary artery stenosis. Circulation 1994;89:2332-2341
53. Glover DK, Okada RD: Myocardial technetium 99m sestamibi kinetics after reperfusion in a canine model. Am Heart J 1993;125:657-666
54. Taillefer R, Primeau M, Costi P, Lambert R, Léveillé J, Latour Y: Technetium-99m-sestamibi myocardial perfusion imaging in detection of coronary artery disease: Comparison between initial (1-hour) and delayed (3-hour) postexercise images. J Nucl Med 1991;32:1961-1965
55. Villanueva-Meyer J, Mena I, Diggles L, Narahara KA: Assessment of myocardial perfusion defect size after early and delayed SPECT imaging with technetium-99m-hexakis 2-methoxyisobutyl isonitrile after stress. J Nucl Med 1993;34:187-192
56. Palmas W, Friedman JD, Diamond GA, Silber H, Kiat H, Berman DS: Incremental value of simultaneous assessment of myocardial function and perfusion with technetium-99m sestamibi for prediction of extent of coronary artery disease. J Am Coll Cardiol 1995;25:1024-1031
57. Villanueva-Meyer J, Mena I, Narahara KA: Simultaneous assessment of left ventricular wall motion and myocardial perfusion with technetium-99m-methoxy isobutyl isonitrile at stress and rest in pa- tients with angina: Comparison with thallium-201 SPECT. J Nucl Med 1990;31:457-463
58. Mannting F, Morgan-Mannting MG: Gated SPECT with technetium-99m-sestamibi for assessment of myocardial perfusion abnormalities. J Nucl Med 1993;34:601-608
59. DePuey EG, Rozanski A: Using gated technetium-99m-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifact. J Nucl Med 1995;36:952-955
60. Quaife RA, Corbett JR: The presence of segmental thickening by gated sestamibi SPECT predicts rest T1-201 segmental viability (abstr). Circulation 1994:90(suppl):I-11
61. Chua T, Kiat H, Germano G, Maurer G, van Train K, Friedman J, Berman D: Gated technetium-99m-sestamibi for simultaneous assessment of stress myocardial perfusion, postexercise regional ventricular function and myocardial viability. J Am Coll Cardiol 1994;23:1107-1114
62. Maunoury C, Chen CC, Chua KB, Thompson CJ: Quantification of left ventricular function with thallium-201 and technetium-99m-sestamibi myocardial gated SPECT. J Nucl Med 1997;38:958-961
63. Worsley DF, Fung AY, Jue J, Burns RJ: Identification of viable myocardium with technetium-99m-MIBI infusion. J Nucl Med 1995;36:1037-1039
64. Galli M, Marcassa C, Imparato A, Campini R, Orrego PS, Giannuzzi P: Effects of nitroglycerin by technetium-99m sestamibi tomoscintigraphy on resting regional myocardial hypoperfusion in stable patients with healed myocardial infaction. Am J Cardiol 1994;74:843-848
65. Bisi G, Sciagra R, Santoro G, Fazzini FP: Rest technetium-99m-sestamibi tomography in combination with short-term administration of nitrates: Feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol 1994;24:1282-1289
66. Nakajima K, Taki J, Shuke N, Bunko H, Takata S, Hisada K: Myocardial perfusion imaging and dynamic analysis with technetium-99m-tetrofosmin. J Nucl Med 1993;34:1478-1484
67. Rigo P, Leclercq B. Itti R, Lahiri A, Braat S: Technetium-99m-tetrofosmin myocardial imaging: A comparison with thallium-201 and angiography. J Nucl Med 1994;35:587-593
68. 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group. Circulation 1995;91:313-319
69. Sinusas AJ, Shi Q, Saltzberg MT, Vitols P, Jain D, Wackers FJ, Zaret BL: Technetium-99m-tetrofosmin to assess myocardial blood flow: Experimental validation in an intact canine model of ischemia. J Nucl Med 1994;35:664-671
70. Koplan BA, Beller GA, Ruiz M, Yang JY, Watson DD, Glover DK: Comparison between thallium-201 uptake and technetium-99m-tetrofosmin uptake with sustained low flow and profound systolic dysfunction. J Nucl Med 1996;37:1398-1402
71. 99mTc-tetrofosmin for the assessment of myocardial viability in patients with severe left ventricular dysfunction (abstr). J Nucl Cardiol 1995:2(suppl):S23
72. Hendel RC, Dahlberg ST, Weinstein H. Leppo JA: Comparison of teboroxime and thallium for the reversibility of exercise-induced myocardial perfusion defects. Am Heart J 1993;126:856-862
73. Stewart RE, Schwaiger M, Hutchins GD, Chiao PC, Gallagher KP, Nguyen N, Petry NA, Rogers WL: Myocardial clearance kinetics of technetium-99m-SQ30217: A marker of regional myocardial blood flow. J Nucl Med 1990;31:1183-1190
74. Links JM, Frank TL, Becker LC: Effect of differential tracer washout during SPECT acquisition. J Nucl Med 1991;32:2253-2257
75. Johnson LL, Seldin DW: Clinical experience with technetium-99m teboroxime, a neutral, lipophilic myocardial perfusion imaging agent. Am J Cardiol 1990;66:63E-67E
76. 99mTc-teboroxime with thallium for myocardial imaging in the presence of a coronary artery stenosis. Circulation 1991;84:1796-1807
77. Hendel RC, Gerson MC, Verani MS, Miller DD, Cerqueira MD, Botvinick EH, McMahon M, Wackers FJ: Perfusion imaging with Tc-99m furifosmin (Q12): Multicenter phase III trial to evaluate safety and comparative efficacy (abstr). Circulation 1994;90(suppl):I-449
78. Pasqualini R, Duatti A, Bellande E, Comazzi V, Brucato V, Hoffschir D, Fagret D, Comet M: Bis(dithiocarbamato) nitrido technetium-99 radiopharmaceuticals: A class of neutral myocardial imaging agents. J Nucl Med 1994;35:334-341
79. Sandier MP, Patton JA: Fluorine 18-labeled fluorodeoxyglucose myocardial single-photon emission computed tomography: An alternative for determining myocardial viability. J Nucl Cardiol 1996;3:342-349